Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282138 | 0.99 | TRPA1 (0.32) | TRPA1LTB4RLTB4R2HSP90AB1GRM2 | |
| SCHEMBL1282025 | 0.96 | TRPA1 (0.32) | TRPA1HSP90AB1NR3C1PGRNR3C2 | |
| SCHEMBL1283158 | 0.90 | S1PR4 (0.34) | LTB4RLTB4R2S1PR4S1PR1S1PR3 | |
| SCHEMBL1282484 | 0.90 | L3MBTL1 (0.39) | — | |
| SCHEMBL1283316 | 0.89 | L3MBTL1 (0.40) | — | |
| SCHEMBL1282493 | 0.86 | GAA (0.35) | S1PR4 | |
| SCHEMBL1281750 | 0.86 | DHFR (0.37) | S1PR4NR3C1PGRNR3C2 | |
| SCHEMBL1282179 | 0.86 | FDPS (0.36) | — | |
| SCHEMBL1282661 | 0.83 | — | — | |
| SCHEMBL1282504 | 0.82 | L3MBTL1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | ERG28, CYP51A1, DPM1 | TRPA1 1525/4885LTB4R 4172/4885LTB4R2 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.